Amyotrophic Lateral Sclerosis News and Research

RSS

First edition: September 15, 2009

Today's headlines zero in on the soon-to-be unveiled Baucus health bill. Reports indicate it likely will address many GOP concerns but also raising new issues for some Democrats.

15 Sep 2009

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).

10 Sep 2009

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial demonstrating that ACE-031 increased lean body mass and muscle volume. The results from this randomized, placebo-controlled study were presented at the 14th International Congress of the World Muscle Society in Geneva, Switzerland.

10 Sep 2009

Three genes linked to Lou Gehrig's disease

Michigan Technological University researchers have linked three genes to the most common type of amyotrophic lateral sclerosis (ALS), generally known as Lou Gehrig's disease.

10 Sep 2009

Safeway raises funds to support neuromuscular disease medical research and therapies

Safeway Inc. announced today it has raised a record $10.2 million to support medical research and services for the millions of people living with neuromuscular diseases. The funds were raised during Safeway’s annual Muscular Dystrophy Association (MDA) campaign, a five-week endeavor to highlight the need to find cures and treatments for muscular dystrophy and related diseases, and presented during the Jerry Lewis MDA Telethon in Las Vegas Labor Day weekend.

9 Sep 2009

Cytrx to submit revised protocol for arimoclomol Phase IIb clinical trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.

8 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Knopp Neurosciences Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of KNS-760704 in amyotrophic lateral sclerosis (ALS).

2 Sep 2009

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading manufacturing contractor, in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product.

31 Aug 2009

Veterans receive false health scare

USA Today reports: "More than 1,800 Gulf War veterans were sent letters from the Veterans Administration this month informing them that they had Lou Gehrig's disease — a fatal neurological disease. But at least some of the letters — and the diagnoses — were a mistake."

26 Aug 2009

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for the treatment of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The company expects to begin Phase I clinical studies in 2010.

24 Aug 2009

Knopp Neurosciences to present phase 2 results of drug candidate in amyotrophic lateral sclerosis

Knopp Neurosciences Inc. said the results of a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (ALS) will be presented at the 20th International Symposium on ALS/MND in Berlin on December 9, 2009.

11 Aug 2009

Researchers discover why Lou Gehrig's disease speeds along more rapidly in some patients than others

University of Florida scientists have discovered why a paralyzing brain disorder speeds along more rapidly in some patients than others - a finding that may finally give researchers an entry point toward an effective treatment for amyotrophic lateral sclerosis, often referred to as ALS or Lou Gehrig's disease.

9 Jun 2009

Amyotrophic Lateral Sclerosis News and Research

First edition: September 15, 2009

CytRx granted patent for molecular chaperone amplifier drug candidate

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Three genes linked to Lou Gehrig's disease

Safeway raises funds to support neuromuscular disease medical research and therapies

Cytrx to submit revised protocol for arimoclomol Phase IIb clinical trial

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

Veterans receive false health scare

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

Knopp Neurosciences to present phase 2 results of drug candidate in amyotrophic lateral sclerosis

Researchers discover why Lou Gehrig's disease speeds along more rapidly in some patients than others

Nervous system may be culprit in Pompe disease

oct3 protein key to Parkinson's, drug addiction

Glutamate identified as predictor of disease progression in multiple sclerosis

Scientists suggest a mechanism for how lithium works in bipolar treatment

Stem cell therapy used to fight amyotrophic lateral sclerosis

Coffee, caffeine and amyotrophic lateral sclerosis

Rochester scientist wins major award for Alzheimer's research

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News